文献速递免疫规划传染病防控与疫情报告

越南婴儿两种轮状病毒疫苗配方的安全性与免疫原性比较

Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants.
PubMed 文献 · Vaccine · 2021-07-01

一项在越南健康婴儿中开展的3期随机、部分双盲、阳性对照研究,比较ROTAVIN(第二代液体候选疫苗)与ROTAVIN-M1(已注册冻干疫苗)的两剂次接种方案。结果显示ROTAVIN的免疫原性非劣效于ROTAVIN-M1,且安全性相似,未报告肠套叠或死亡病例。

要点

  • ROTAVIN与ROTAVIN-M1两剂次接种后抗轮状病毒IgA GMC比值为1.38(95%CI 1.02,1.86),满足非劣效标准。
  • 两组 solicited reactions 发生率分别为35.4%和37.2%,安全性相似。
  • 研究中未报告肠套叠或死亡病例。

核心结论

  • ROTAVIN在越南婴儿中两剂次接种的免疫原性非劣效于ROTAVIN-M1,且安全性相似。

研究设计与样本

  • 3期随机、部分双盲、阳性对照研究,纳入825名60-91日龄健康越南婴儿,按2:1随机接种两剂ROTAVIN或ROTAVIN-M1,间隔8周。

主要发现

  • 接种后ROTAVIN组抗轮状病毒IgA GMC为48.25(95%CI 40.59,57.37),ROTAVIN-M1组为35.04(95%CI 27.34,44.91)。
  • IgA GMC比值为1.38(95%CI 1.02,1.86),95%CI下限大于0.5,满足非劣效标准。
  • 297名(36.0%)参与者报告605例次 solicited reactions,ROTAVIN组35.4%,ROTAVIN-M1组37.2%。
  • 研究期间未报告肠套叠或死亡病例。

关键数值与推荐

  • 非劣效标准:ROTAVIN/ROTAVIN-M1接种后抗轮状病毒IgA GMC比值的95%CI下限需大于0.5。

临床怎么用

  • ROTAVIN可作为越南及湄公河地区预防轮状病毒腹泻的规划用疫苗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: ROTAVIN-M1® (licensed, frozen vaccine) and ROTAVIN (second-generation, liquid candidate vaccine) are two rotavirus vaccine formulations developed from a live attenuated G1P8 (KH0118) strain by Center for Research and Production of Vaccines and Biologicals (POLYVAC), Vietnam. This study compared the safety and immunogenicity of these two formulations. METHODS: A Phase 3, randomized, partially double-blinded, active-controlled study was conducted in healthy infants aged 60-91 days in Vietnam. Infants received two doses of ROTAVIN or ROTAVIN-M1 in a ratio of 2:1 with an interval of 8 weeks. Solicited reactions were collected for 7 days after each vaccination. Blood samples were collected pre-vaccination and 4 weeks after the second vaccination in a subset of infants. Non-inferiority criteria required that the lower bound of 95% confidence intervals (CIs) of the post-vaccination anti-rotavirus IgA GMC (Geometric Mean Concentration) ratio of ROTAVIN/ROTAVIN-M1 should be >0.5. A co-primary objective was to compare the safety of the two vaccines in terms of solicited reactions. RESULTS: A total of 825 infants were enrolled. The post-vaccination GMC was 48.25 (95% CI: 40.59, 57.37) in the ROTAVIN group and 35.04 (95% CI: 27.34, 44.91) in the ROTAVIN-M1 group with an IgA GMC ratio of 1.38 (95% CI: 1.02, 1.86) thus meeting the pre-set criteria for non-inferiority. A total of 605 solicited reactions were reported in 297 (36.0%) participants with 35.4% in the ROTAVIN group and 37.2% in the ROTAVIN-M1 group. There were no cases of intussusception or death reported in the study. CONCLUSIONS: Based on the data generated, it can be concluded that ROTAVIN is immunologically non-inferior and has similar safety profile to ROTAVIN-M1 when administered to infants in a two-dose schedule. Therefore, it can be considered as a more suitable option for programmatic use to prevent rotavirus diarrhoea in Vietnam and the Mekong region. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT03703336, October 11, 2018.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thiem VD, Anh DD, Ha VH, et al. Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants. Vaccine. 2021. PMID: 34218961. doi:10.1016/j.vaccine.2021.06.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。